BİRİNCİLİ AÇIQBUCAQLI QLAUKOMANIN MÜALİCƏSİNDƏ PROSTAQLANDİN F2α YENİ ANALOQUNUN KLİNİK EFFEKTİVLİYİ

Xülasə

SUMMURY

Aim of this study was to assess clinical effcacy and tolerability of Tafotan (tafuprost 0,0015%) in the treatment of primary open angle glaucoma (POAG).

Materials and methods
31 patients (59 eyes) with primary diagnosed POAG, intraocular pressure (IOP) up to 40 mmHg and macular zone without pathology who were prescribed preservative-free Tafotan once daily were included in this prospective study.

Results
The mean follow-up period was 12 months. Mean baseline IOP in POAG patients was 31,7 ± 0,6 mmHg. In eyes with POAG mean IOP was 19 mmHg at fnal follow-up. In 20,3% eyes with POAG prescription of additional antiglaucomatous drops was needed during follow-up. In 6,8% eyes with POAG IOP could not be controlled medicamentously and antiglaucomatous surgery was required. Local adverse effects of tafuprost were recorded in 5 (16,1%) patients.

Conclusion
Tafuprost is clinically effective in the treatment of POAG with 12 months follow-up. Use of this type of prostaglandin is accompanied by low rate of local adverse effects.